Equillium, Inc.
EQ
Rank in Stocks
#19886
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on... Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Share Price
$1.50
Last synced: 2026-11-09
Market Cap
$95.11M
Change (1 day)
-0.66%
Change (1 year)
54.48%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Equillium, Inc. (EQ)
Category
Healthcare
Operating Margin for Equillium, Inc. (EQ)
Operating Margin as of November 2026 TTM: 0.00%
According to Equillium, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Equillium, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -20.12% | -50.00% |
| 2023 | -40.24% | -89.78% |
| 2022 | -393.91% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Equillium, Inc.'s operating margin
What was Equillium, Inc.'s operating margin in 2025?
In 2025, Equillium, Inc.'s operating margin was 0.00%, compared with -20.12% in 2024.
How has Equillium, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Equillium, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2022 (-393.91%).
How does Equillium, Inc.'s operating margin compare with similar companies?
Equillium, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.